• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

    5/1/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email
    • $32.5 million funded at close; up to $17.5 million of additional capital available at the Company's option, subject to the achievement of certain revenue thresholds.
    • Capital from the transaction is expected to support execution of strategic plan and fuel continued growth.
    • With this new structure, debt amortization is deferred from the end of 2025 to 2028, allowing the time to generate funds from operations to support the Company's cash flow.

    NEW YORK, May 1, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced the closing of a debt financing facility for up to $50 million provided by Rand Capital and Callodine Group. The capital refinances the Company's existing credit facility, providing additional operational flexibility and supporting the commercial execution of its Business-to-Business-to-Consumer ("B2B2C") strategy across pharmaceutical companies, self-insured employers and payer channels.

    DarioHealth Logo

    Under the terms of the credit agreement (the "Credit Agreement"), the Company borrowed $32.5 million at closing. In addition, an aggregate of up to an additional $17.5 million is available to be drawn down at the Company's option, based on the achievement of certain revenue thresholds. The Credit Agreement has a five-year term that matures in April 2030. In connection with the funding of the closing amount, the Company also issued a warrant to purchase  2,114,140 shares of the Company's common stock, with an exercise price of $0.8278. In addition, up to $2.5 million of the loaned amount can be converted into shares of the Company's common stock at a price of $0.9933 per share. With the refinancing and current cash on hand, the Company believes that deferring the debt amortization from the end of 2025 to 2028 will allow the time to generate funds from operations to support the Company's cash flow.

    "We are excited to partner with Rand Capital and Callodine Group," said Erez Raphael, Chief Executive Officer of Dario. "This transaction provides us with the needed flexibility to execute upon our strategic growth initiatives. This financing reduces our near-term need for debt principal payments under our previous credit agreement. Given the Rand Capital and Callodine Group investment teams' history of successfully funding innovative healthcare companies with credit solutions, we view this as a strong validation of our platform and vision."

    Winston Black, General Partner of Rand Capital, added, "We are excited to support Dario as they commercialize what we believe is one of the most comprehensive, integrated, hyper-personalized chronic care management platforms on the market today. Dario is addressing a multi-billion-dollar market opportunity to empower users with tools that produce better care at lower cost to the health system, as they improve management of expensive chronic diseases in between physician visits."

    Dario was represented in this transaction by Sullivan & Worcester LLP who served as legal counsel. Rand Capital and Callodine Group were represented in this transaction by Holland & Knight LLP, who served as legal counsel.

    About DarioHealth Corp. 

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. 

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

    Cautionary Note Regarding Forward-Looking Statements 

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits of the Credit Agreement, including that the funds will be used to support the execution of its business plan and fuel continued growth, the potential for an additional draw down of $17.5 million at the Company's option, based on the achievement of certain revenue thresholds, that the proceeds from the Credit Agreement and current cash on hand, it expects to have the time to generate funds from operations to support the Company's cash flow; that the transaction will provide the Company with the needed flexibility to execute its strategic growth initiatives; and that the Company is addressing a multi-billion-dollar market opportunity. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

    DarioHealth Corporate Contact

    Mary Mooney

    VP Marketing

    [email protected]

    +1-312-593-4280 

    DarioHealth Investor Relations Contact 

    Kat Parrella

    Investor Relations Manager 

    [email protected]

    +315-378-6922 

    Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-closes-strategic-refinancing-of-existing-debt-facility-of-up-to-50-million-to-provide-additional-operational-flexibility-and-support-growth-initiatives-302443987.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DarioHealth Reports First Quarter 2025 Financial and Operating Results

      First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5

      5/14/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

      $32.5 million funded at close; up to $17.5 million of additional capital available at the Company's option, subject to the achievement of certain revenue thresholds.Capital from the transaction is expected to support execution of strategic plan and fuel continued growth.With this new structure, debt amortization is deferred from the end of 2025 to 2028, allowing the time to generate funds from operations to support the Company's cash flow.NEW YORK, May 1, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced the closing of a debt financing facility for up to $50 million provided by Rand Capital and Callodine

      5/1/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DarioHealth downgraded by TD Cowen with a new price target

      TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      1/29/25 7:36:04 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

      5/13/22 9:01:42 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Aegis Capital reiterated coverage on DarioHealth with a new price target

      Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

      1/26/22 10:35:44 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    SEC Filings

    See more
    • SEC Form DEF 14A filed by DarioHealth Corp.

      DEF 14A - DarioHealth Corp. (0001533998) (Filer)

      5/30/25 5:16:55 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - DarioHealth Corp. (0001533998) (Filer)

      5/29/25 4:05:51 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by DarioHealth Corp.

      S-3 - DarioHealth Corp. (0001533998) (Filer)

      5/28/25 4:15:52 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Financials

    Live finance-specific insights

    See more
    • DarioHealth Reports First Quarter 2025 Financial and Operating Results

      First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5

      5/14/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results

      Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas

      3/10/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      12/13/24 4:05:12 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      10/29/24 11:45:28 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

      SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

      2/14/24 4:51:40 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Franco-Yehuda Chen was granted 500,000 shares (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:02:48 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Franco-Yehuda Chen

      3 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:01:27 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

      3 - DarioHealth Corp. (0001533998) (Issuer)

      3/7/25 4:05:19 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      11/14/24 4:15:15 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/12/24 4:37:42 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/10/24 6:00:13 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    See more
    • DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

      Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

      2/27/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

      After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

      6/5/24 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care